Contents of this document
Summary of Q&A2026年9月期 通期予想4 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,035 million-3.7%
Operating profit¥-356 million
Full-year earnings forecast
Net Sales
¥1,035 million
Operating profit
¥-356 million
売上高+営業外収益
¥1,569 million
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
- 独自の経営指標として、補助金・助成金を含む『売上高+営業外収益』を用いる理由
- 営業利益の赤字拡大の要因と先行投資の内訳
- 営業赤字の縮小および国の補助事業からの脱却に向けた方針
- 東証スタンダード市場への区分変更を目指す理由とタイミング
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- 本社販管費(本社人材投資等)¥-60 million
- 外注費(海外プロジェクト推進等)¥-110 million
- 研究開発費(バイオものづくり革命推進事業の設備投資による減価償却費等)¥-106 million
- 研究開発費(上記以外の研究員人材投資等)¥-76 million
- 営業利益の前年差増減合計¥-352 million
New initiatives
- 東証スタンダード市場への市場区分変更申請に向けた準備
- 2028年9月期以降の垂直統合型バイオファウンドリによる自社販売モデルの推進
Key KPIsA metric the company considers important as a management benchmark.
- 売上高+営業外収益¥1,569 millionYear on year against the same period last year+27.2%
| Item | Details |
|---|---|
| Document type | Summary of Q&A |
| Fiscal Period Covered | 2026年9月期 通期予想 |
| Net Sales | ¥1,035 million (YoY -3.7%) |
| Operating profit | ¥-356 million |
| Full-year earnings forecast | Net Sales ¥1,035 million / Operating profit ¥-356 million / Ordinary income Not disclosed / Net income Not disclosed / 売上高+営業外収益 ¥1,569 million |
| Breakdown of Factors Affecting the Change | Factors 本社販管費(本社人材投資等) / Amount ¥-60 million, Factors 外注費(海外プロジェクト推進等) / Amount ¥-110 million, Factors 研究開発費(バイオものづくり革命推進事業の設備投資による減価償却費等) / Amount ¥-106 million, Factors 研究開発費(上記以外の研究員人材投資等) / Amount ¥-76 million, Factors 営業利益の前年差増減合計 / Amount ¥-352 million |
| Key KPIs | Indicator name 売上高+営業外収益 / Value ¥1,569 million / Year on year against the same period last year ¥27.2 million |
| Key points of the Q&A | 独自の経営指標として、補助金・助成金を含む『売上高+営業外収益』を用いる理由, 営業利益の赤字拡大の要因と先行投資の内訳, 営業赤字の縮小および国の補助事業からの脱却に向けた方針, 東証スタンダード市場への区分変更を目指す理由とタイミング |
| New initiatives | 東証スタンダード市場への市場区分変更申請に向けた準備, 2028年9月期以降の垂直統合型バイオファウンドリによる自社販売モデルの推進 |
Items this document does not state (22)
Ordinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / Share
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.